While Biocon reported a dismal earnings show for Q2, the management as well as brokerage remain hopeful for a better second half of FY25. Key triggers for the stock include clarity over USFDA ...

Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.

Rapid weight loss can cause a greater loss of muscle mass than losing weight slowly. The popularity of newer weight-loss ...

Wegovy reduced arthritic knee pain in study subjects with high BMI. Unknown: the exact mechanism or whether it would prevent knee replacement surgery.

One in eight American adults, about 12%, has taken Ozempic or a similar drug for diabetes or weight loss, recent research ...

Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of ...

Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a ...

Obesity treatment shifts from surgery to drugs as bariatric procedures decline by 25.6% and GLP-1 receptor agonist use jumps ...

It's no secret that doctors are helping many people lose weight by prescribing GLP-1 medications like Ozempic, Wegovy, ...

LLY had $11.4 billion in revenue for the quarter (up 20% versus Q3 figures from last year), with a net income of $970 million ...

The FDA on Wednesday updated its drug shortage database to say that all dosages and versions of Novo Nordisk's Wegovy and Ozempic are ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...